Anoikis is a type of programmed cell death, apoptosis induced by loss of cell adhesion or inappropriate cell adhesion. Anoikis is involved in a variety of pathological processes, including carcinogenesis. Cancer cells can promote anoikis resistance primarily by regulating integrins and initiating epithelial-mesenchymal transition (EMT). Cancer cells metastasize or migrate to distant sites after EMT or extracellular matrix (ECM) serial dissection processes, colonize and proliferate at new sites, eventually leading to tumor spread and loss of surgical opportunities. Cancer cells can employ multiple mechanisms to eliminate anoikis and promote invasion and metastasis. Cancer cells strongly influence resistance to anoikis by promoting oncogenic signaling of pro-survival pathways or changes in the acidic environment and generating reactive oxygen species (ROS) in the tumor microenvironment. So far, the role of anoikis in tumors and its underlying mechanisms remain unclear and require further investigation.

Recently, it has been suggested that one of the future methods for the treatment and prevention of disease may be the induction of programmed death of abnormal cells. Because it can slow down the progression of the disease, and eventually lead to tumor cell anoikis, to cure the disease. Some studies have implicated several molecular / pathway alterations in preventing disease in metastatic cancer, so a comprehensive analysis of the molecular and functional biology of tumor cell anoikis resistance will provide important details regarding cancer metastasis, allowing us to identify novel therapeutic targets for cancer cell spread and ultimately secondary tumor formation.
Currently, the research on drug delivery systems has caused a boom in the medical community. Studies are developing drug delivery systems to induce tumor cells anoikis to cure the disease because it can reduce the toxic side effects and improve the therapeutic effect. In addition, it is also very important to find prognostic markers for tumors, which will become an important target in the process of cancer treatment and be necessary to develop targeted drugs for tumors.
Scope and Information for authors (approx. 100-150 words)
Define the scope of the Research Topic, listing specific themes you would like contributors to address. Indicate the types of manuscripts you are interested in.
This Research Topic focuses on the mechanism of anoikis in the development of tumors and the development of new anoikis-based cancer treatment strategies and discovers the relationship between anoikis and tumor immunity to develop a novel anoikis-based signature to predict the prognosis of cancer patients accurately and to characterize the immune landscape for improved treatment selection.
We welcome original research articles and reviews. Potential subtopics include but are not limited to the following:
• The molecular mechanism and clinical significance of anoikis; Anoikis and cancer immunity;
• Anoikis and immune response homeostasis;
• Construction of immunotherapy evaluation models based on the key genes of anoikis;
• Construction of cancer prognosis models based on the key genes of anoikis;
• Verification of the function based on the key genes of anoikis;
• Developing novel cancer-targeted therapy strategies based on anoikis and screening potential therapeutic drugs.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.

Submit your idea

Authors

Frontiers in Pharmacology

Participating Journals

Impact